Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

This study sought to determine the relationship of KIM-1 levels with adverse clinical outcomes in acute decompensated heart failure (ADHF).

Multivariable logistic and Cox models were used to assess the relationship between KIM-1 levels and outcomes during and after ADHF.

Why It Was Studied

Kidney injury molecule (KIM)-1 is a biomarker expressed by the nephron in acute tubular injury, and is a sensitive and specific marker for early acute kidney injury.

Although commonly measured in urine, KIM-1 levels are also detectable in plasma, but its clinical and prognostic utility in ADHF is unknown.

Who Took Part

According to the abstract, 874 subjects were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Blinding on both sides kept the subjects and researchers unaware of who received BNP (Nesiritide).

What Was Measured

Although commonly measured in urine, KIM-1 levels are also detectable in plasma, but its clinical and prognostic utility in ADHF is unknown.

The subject headings attached to it are Acute Disease, Biomarkers, Heart Failure, Hepatitis A Virus Cellular Receptor 1, Hospital Mortality, Inpatients and Kaplan-Meier Estimate.

The authors tagged it with the keywords acute heart failure, acute kidney injury, kidney injury molecule-1 and nesiritide.

What This Means in Plain Language

The paper is a randomized and double-blind study of BNP (Nesiritide) in 874 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (JACC. Heart failure), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.